Liang Li1, Ambrose Cheung2, Arnold S Bayer1,3,4, Liang Chen5, Wessam Abdelhady1, Barry N Kreiswirth5, Michael R Yeaman1,3,6,4, Yan Q Xiong1,3,4. 1. Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center. 2. Dartmouth Medical School, Hanover, New Hampshire. 3. Division of Infectious Diseases. 4. David Geffen School of Medicine at UCLA, Los Angeles, California. 5. Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark. 6. Division of Molecular Medicine, Los Angeles County-Harbor-UCLA Medical Center, Torrance.
Abstract
BACKGROUND: The global regulator sarA modulates virulence of methicillin-resistant Staphylococcus aureus (MRSA) via regulation of principal virulence factors (eg, adhesins and toxins) and biofilm formation. Resistance of S. aureus strains to β-lactam antibiotics (eg, oxacillin) depends on the production of penicillin-binding protein 2a (PBP2a), encoded by mecA METHODS: In the present study, we investigated the impact of sarA on the phenotypic and genotypic characteristics of oxacillin resistance both in vitro and in an experimental endocarditis model, using prototypic healthcare- and community-associated MRSA parental and their respective sarA mutant strain sets. RESULTS: All sarA mutants (vs respective MRSA parental controls) displayed significant reductions in oxacillin resistance and biofilm formation in vitro and oxacillin persistence in an experimental endocarditis model in vivo. These phenotypes corresponded to reduced mecA expression and PBP2a production and an interdependency of sarA and sigB regulators. Moreover, RNA sequencing analyses showed that sarA mutants exhibited significantly increased levels of primary extracellular proteases and suppressed pyrimidine biosynthetic pathway, argininosuccinate lyase-encoding, and ABC transporter-related genes as compared to the parental strain. CONCLUSIONS: These results suggested that sarA regulates oxacillin resistance in mecA-positive MRSA. Thus, abrogation of this regulator represents an attractive and novel drug target to potentiate efficacy of existing antibiotic for MRSA therapy.
BACKGROUND: The global regulator sarA modulates virulence of methicillin-resistant Staphylococcus aureus (MRSA) via regulation of principal virulence factors (eg, adhesins and toxins) and biofilm formation. Resistance of S. aureus strains to β-lactam antibiotics (eg, oxacillin) depends on the production of penicillin-binding protein 2a (PBP2a), encoded by mecA METHODS: In the present study, we investigated the impact of sarA on the phenotypic and genotypic characteristics of oxacillin resistance both in vitro and in an experimental endocarditis model, using prototypic healthcare- and community-associated MRSA parental and their respective sarA mutant strain sets. RESULTS: All sarA mutants (vs respective MRSA parental controls) displayed significant reductions in oxacillin resistance and biofilm formation in vitro and oxacillin persistence in an experimental endocarditis model in vivo. These phenotypes corresponded to reduced mecA expression and PBP2a production and an interdependency of sarA and sigB regulators. Moreover, RNA sequencing analyses showed that sarA mutants exhibited significantly increased levels of primary extracellular proteases and suppressed pyrimidine biosynthetic pathway, argininosuccinate lyase-encoding, and ABC transporter-related genes as compared to the parental strain. CONCLUSIONS: These results suggested that sarA regulates oxacillin resistance in mecA-positive MRSA. Thus, abrogation of this regulator represents an attractive and novel drug target to potentiate efficacy of existing antibiotic for MRSA therapy.
Authors: Binh An Diep; Steven R Gill; Richard F Chang; Tiffany HaiVan Phan; Jason H Chen; Matthew G Davidson; Felice Lin; Jessica Lin; Heather A Carleton; Emmanuel F Mongodin; George F Sensabaugh; Françoise Perdreau-Remington Journal: Lancet Date: 2006-03-04 Impact factor: 79.321
Authors: Wessam Abdelhady; Liang Chen; Arnold S Bayer; Kati Seidl; Michael R Yeaman; Barry N Kreiswirth; Yan Q Xiong Journal: J Antimicrob Chemother Date: 2015-01-05 Impact factor: 5.790
Authors: Susan Boyle-Vavra; Shouhui Yin; Dae Sun Jo; Christopher P Montgomery; Robert S Daum Journal: Antimicrob Agents Chemother Date: 2012-10-15 Impact factor: 5.191
Authors: Michael M Mwangi; Shang Wei Wu; Yanjiao Zhou; Krzysztof Sieradzki; Herminia de Lencastre; Paul Richardson; David Bruce; Edward Rubin; Eugene Myers; Eric D Siggia; Alexander Tomasz Journal: Proc Natl Acad Sci U S A Date: 2007-05-21 Impact factor: 11.205
Authors: Yongliang Fang; Jack R Kirsch; Liang Li; Seth A Brooks; Spencer Heim; Cynthia Tan; Susan Eszterhas; Hao D Cheng; Hongliang Zhao; Yan Q Xiong; Karl E Griswold Journal: Antimicrob Agents Chemother Date: 2021-02-17 Impact factor: 5.191
Authors: Liang Li; Wessam Abdelhady; Niles P Donegan; Kati Seidl; Ambrose Cheung; Yu-Feng Zhou; Michael R Yeaman; Arnold S Bayer; Yan Q Xiong Journal: J Infect Dis Date: 2018-09-22 Impact factor: 5.226